Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
Title:
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
Author:
Herbst, Roy S Sun, Yan Eberhardt, Wilfried EE Germonpré, Paul Saijo, Nagahiro Zhou, Caicun Wang, Jie Li, Longyun Kabbinavar, Fairooz Ichinose, Yukito Qin, Shukui Zhang, Li Biesma, Bonne Heymach, John V Langmuir, Peter Kennedy, Sarah J Tada, Hiroomi Johnson, Bruce E